We are honored that our sustainability initiative has been recognized with the CPhI Pharma Award 2020 in the category of ‘Excellence in Pharma: Sustainability’.

The Judging Panel, which is comprised of independent, senior industry experts…

Hyderabad, India, October 5, 2020

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) has joined the Science Based Targets initiative’s (SBTi) business ambition for 1.5°C, becoming the first Indian and the third Asian phar…

Hyderabad, India, July 01, 2020

Hyderabad, India, July 01, 2020 - Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:RDY, hereafter referred to as “Dr. Reddy’s”) announces partnering with FUJIFILM Corporation through FUJIFILM T…

Certificate of Suitability (CEP) for the API Levofloxacin Hemihydrate has been granted.

Dr. Reddy’s is among the first companies to receive the CEP from the European Directorate for the Quality of Medicines (EDQM). Together with our expand…

Dr. Reddy’s has filed the US DMF for Apalutamide, which expands our oncology API portfolio further and demonstrates our strength in R&D and regulatory affairs.

Our API partners now have access to the US DMF and validated batch samples.…

December 2019